Rodman & Renshaw Reiterates EpiCept Market Outperform, $2 PT

Rodman & Renshaw reiterated its EpiCept

Market Outperform rating and $2 price target in a research report published today. In the report, Rodman & Renshaw states, "The potential to initiate a new Phase 3 trial of Ceplene with overall survival as an endpoint creates a path forward for the drug in the US, and the FDA's recommendation of including an IL-2 monotherapy arm creates a more robust study, especially considering that the clinical profile of IL-2 monotherapy in AML remission is largely already known. Additionally, the proposed design for the new Phase 3 trial of Ceplene contains several further improvements (see Table, next page) that could bode well for improving the chances of a positive outcome." Shares of EpiCept were trading at $0.46 at the time of posting, up 9.52% from Friday's market close.